Does Aetna (CVS Health) Cover Addyi (Flibanserin)?

What Is Addyi and Why Does Coverage Get Complicated?

Addyi (flibanserin) is the first FDA-approved pharmacotherapy for generalized acquired HSDD in premenopausal women. The FDA granted approval on August 18, 2015, based on three Phase 3 trials, including BEGONIA (N=1,378), which demonstrated a statistically significant increase in satisfying sexual events (SSEs) and a decrease in distress scores compared with placebo over 24 weeks 1. Coverage is complicated because HSDD was historically under-recognized, and many insurer policies were written before strong clinical trial data existed. Aetna, now operating under CVS Health, applies a moderate-to-high prior authorization burden that reflects both cost concerns and the REMS program requirements attached to the drug 2.

Flibanserin works as a postsynaptic serotonin 1A receptor agonist and serotonin 2A receptor antagonist, a mechanism entirely different from sildenafil or testosterone products 3. Because it acts centrally on neurotransmitter balance rather than on vascular or hormonal pathways, it occupies a unique therapeutic category. That novelty is partly why insurers built restrictive formulary policies around it rather than grouping it with existing female sexual health drugs. The FDA label carries a REMS (Risk Evaluation and Mitigation Strategy) requiring prescriber certification due to hypotension and syncope risk when combined with alcohol or CYP3A4 inhibitors 4.

Aetna Formulary Placement for Addyi

Aetna typically places Addyi on a specialty or non-preferred brand tier, meaning the member cost share is higher than generic alternatives. On most Aetna commercial PPO and HMO plans, flibanserin sits on Tier 3 or Tier 4, depending on the specific plan document. Members should pull their Summary of Benefits and Coverage (SBC) or call the number on the back of their card to confirm tier placement, since Aetna's formulary varies by employer group and plan year 5.

Specialty tier placement is not accidental. The Institute for Clinical and Economic Review (ICER) reviewed female sexual dysfunction therapies and noted that cost-effectiveness thresholds for flibanserin depend heavily on how utilities are assigned to SSE improvements 6. Aetna's pharmacy and therapeutics (P&T) committee uses that kind of pharmacoeconomic data when setting formulary tier. Regardless of tier, a prior authorization is almost always required before the pharmacy will dispense the drug under an Aetna benefit.

Aetna Prior Authorization Criteria for Addyi

Aetna requires prior authorization for flibanserin. The PA criteria Aetna applies generally mirror the FDA-approved indication and the clinical evidence base. Your prescriber will typically need to document all of the following before Aetna issues an approval 7:

1. Confirmed diagnosis of HSDD. The treating clinician must document a diagnosis of generalized acquired HSDD using DSM-5 criteria for female sexual interest/arousal disorder (FSIAD) or the prior DSM-IV-TR HSDD classification. HSDD is defined as persistent deficiency of sexual desire causing marked distress or interpersonal difficulty, not attributable to another medical condition, medication effect, or relationship problem 8.

2. Premenopausal status. Addyi holds FDA approval only for premenopausal women. Aetna will deny requests for postmenopausal patients as an off-label use. Your clinician must document menstrual history or relevant hormonal labs.

3. Rule-out of contributing factors. The prescriber should document that depression, relationship distress, thyroid dysfunction, hypoactive testosterone, and medication-induced sexual side effects (SSRIs being the most common) have been evaluated and addressed where clinically appropriate 9.

4. Step therapy completion. See the section below for detail on which prior treatments Aetna requires before approving flibanserin.

5. REMS certification. The prescribing provider must be certified under the Addyi REMS program, and many Aetna PA forms ask for the prescriber's REMS certification number 10.

The PA form itself is typically submitted by the prescribing clinician or their office staff through Aetna's provider portal, by fax, or through a pharmacy benefits manager (PBM) portal. CVS Caremark, Aetna's integrated PBM, processes most of these requests. Turnaround for a standard PA is 72 hours for non-urgent requests; an urgent PA (when a clinician certifies clinical urgency) must be adjudicated within 24 hours under CMS and most state regulations 11.

Step Therapy: What Aetna Requires Before Approving Addyi

Aetna's step therapy protocol for flibanserin generally requires documented trial and inadequate response or intolerance to at least one, and sometimes two, prior treatments. The specific step therapy requirements differ by plan, but commonly include:

Psychotherapy or sex therapy. Cognitive behavioral therapy (CBT) and mindfulness-based therapies have evidence for female sexual dysfunction. A 2016 meta-analysis in the Journal of Sex and Marital Therapy (N=1,980 pooled subjects) found CBT produced moderate effect sizes on desire outcomes 12. Aetna may request documentation of referral, attendance of sessions, or a letter from a therapist confirming inadequate response.

Addressing modifiable causes. If an SSRI is the likely cause of low desire, a trial of dose reduction, switch to bupropion, or adjunct buspirone may be required first 13. Aetna reviewers may look for evidence this was attempted.

Off-label estrogen or testosterone evaluation. Some Aetna plans require documentation that testosterone deficiency has been excluded or treated. Testosterone therapy for women with HSDD has evidence but lacks FDA approval for this indication 14.

Step therapy duration requirements are typically 4 to 12 weeks per step, though Aetna's specific plan documents set the exact timeline. If your prescriber believes step therapy is medically inappropriate (for example, the patient has a contraindication to prior-step therapies), they can request a step therapy exception at the time of PA submission, providing clinical justification.

How to Submit the PA and Maximize Approval Odds

A clean, fully documented PA submission reduces the risk of an automatic denial. These are the elements that most improve approval odds 15:

• Office notes clearly documenting HSDD symptom duration (typically 6 months or more), frequency, and severity using a validated tool such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS).
• Explicit statement of premenopausal status, either by menstrual history or FSH/estradiol labs.
• Documentation of step therapy attempts, with dates and outcomes.
• Prescriber's REMS certification number.
• A letter of medical necessity written by the treating clinician, not a templated form, explaining the clinical decision.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction states: "For women with HSDD, flibanserin is the only FDA-approved pharmacologic option and should be accessible after appropriate clinical evaluation" 16. That language is directly useful in a letter of medical necessity when Aetna's reviewer is weighing whether the request meets clinical criteria.

What Happens When Aetna Denies the PA?

A denial is not the end of the road. Aetna's denial letter must, by federal regulation, include the specific clinical reason for denial and instructions on how to appeal 17. The standard appeal pathway runs in three stages:

Stage 1: Internal appeal. Your prescriber submits a first-level internal appeal within 180 days of the denial notice (check your plan document, as some plans set shorter windows). The appeal should include any new clinical documentation, peer-reviewed literature supporting flibanserin use (citing BEGONIA and FDA approval are both appropriate), and a revised letter of medical necessity 1. Aetna must respond to a standard internal appeal within 30 days; urgent appeals within 72 hours.

Stage 2: Second-level internal appeal or peer-to-peer review. If the first-level appeal fails, your prescriber can request a peer-to-peer telephone review with the Aetna medical director who reviewed the case. This call allows your clinician to present clinical nuances not captured in paperwork. Many denials reverse at this stage when the treating physician speaks directly with the reviewer.

Stage 3: External independent review. If both internal appeal stages fail, patients on fully insured commercial Aetna plans have the right to request an Independent Medical Review (IMR) or External Review through their state insurance commissioner, or through an independent review organization designated under the Affordable Care Act (ACA) 18. The external reviewer is not employed by Aetna and must apply evidence-based clinical criteria. External review approval rates for specialty medications vary by drug and state, but data from the Kaiser Family Foundation analysis of ACA external reviews found that plans are overturned in roughly 39 to 45 percent of external reviews 19.

Self-insured employer plans (ERISA plans) follow a slightly different path. External review for ERISA plans still applies under the ACA, but the governing regulations differ from state law 20.

Aetna Appeal Denied: Next Options

If all internal and external appeal options are exhausted, the following paths remain:

Manufacturer patient assistance program. Sprout Pharmaceuticals, which markets Addyi, offers a copay assistance program for commercially insured patients and a separate patient assistance program for uninsured or underinsured patients. Eligibility and benefit caps change annually, so contact Sprout directly at the Addyi website for current terms 21.

Cash pay with discount cards. GoodRx and similar discount programs may reduce the out-of-pocket cost below the $880 list price at some pharmacies. Cash-pay pricing varies by pharmacy and geography.

Telehealth prescribers with different insurer networks. If your current plan consistently denies HSDD treatment, reviewing your plan options at next open enrollment for plans with more permissive HSDD policies is a reasonable clinical strategy.

State insurance commissioner complaint. Filing a complaint with your state insurance regulator creates a formal record and sometimes prompts insurers to re-review. The National Association of Insurance Commissioners (NAIC) maintains a directory of state regulators 22.

Clinical Evidence Supporting the Flibanserin Coverage Argument

Understanding the trial data helps prescribers write stronger medical necessity letters and helps patients understand why coverage advocates cite specific studies.

The BEGONIA trial (N=1,378 to 24 weeks) published in the Journal of Sexual Medicine in 2014 showed flibanserin 100 mg nightly produced a mean increase of 0.7 SSEs per month versus 0.4 for placebo, with concurrent reduction in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) 1. The FDA's clinical review of the three key trials (combined N=approximately 2,400) noted consistent, statistically significant improvement in SSEs (P<0.001) and desire domain scores across the trials, even as the absolute magnitude of benefit was modest 4.

A secondary analysis published in the Journal of Women's Health (2016) found that women with greater baseline distress scores derived larger absolute benefit from flibanserin, suggesting patient selection matters for treatment response 23. Selecting patients with documented high FSDS-R distress scores for PA submissions strengthens the medical necessity argument.

The Endocrine Society's clinical practice guideline on female sexual dysfunction, published in the Journal of Clinical Endocrinology and Metabolism, notes: "Flibanserin is FDA approved for premenopausal women with HSDD and may be considered when non-pharmacological interventions have been insufficient" 24.

The Manufacturer Savings Card and Aetna Compatibility

Sprout Pharmaceuticals offers a savings card that can reduce cost share for eligible commercially insured patients. Critically, most manufacturer savings cards, including Sprout's, cannot be used as the primary payer alongside government insurance programs (Medicare Part D, Medicaid, TRICARE). For standard Aetna commercial plans, the savings card is generally compatible and may reduce the member's copay significantly 25.

Check current eligibility directly at addyi.com/savings before relying on savings card availability, as annual income caps and program terms change. Some Aetna plans with accumulator adjustment programs (AAPs) or maximizer programs may not allow savings card amounts to count toward the member's deductible or out-of-pocket maximum, which affects overall annual cost 26.

REMS Program Requirements and Their Effect on Coverage

Addyi is one of a small number of drugs with an active REMS that imposes patient and prescriber restrictions. The Addyi REMS requires prescribers to be certified, patients to be counseled about alcohol avoidance and drug interactions (especially CYP3A4 inhibitors like fluconazole), and pharmacies to be enrolled 27. Aetna's PA forms reflect these requirements. An uncertified prescriber submitting a PA for flibanserin will receive an automatic denial on procedural grounds before any clinical review occurs.

CYP3A4 inhibitors commonly used in women of premenopausal age include oral antifungals (fluconazole, itraconazole), some antibiotics (clarithromycin), and grapefruit juice in large quantities. These interactions must be addressed in clinical counseling and may appear as contraindication checks in Aetna's clinical review process 28.

Postmenopausal Use: Why Aetna Will Not Cover It

Addyi holds FDA approval only for premenopausal women. Postmenopausal HSDD is a real and common condition, but flibanserin's key trials enrolled premenopausal patients exclusively. Off-label prescribing for postmenopausal women is clinically practiced in some settings, but Aetna will not cover it under this indication 29. An appeal citing off-label use will almost certainly fail at the internal level, and external review organizations are generally not required to mandate coverage of off-label indications unless state law specifically requires it. Ospemifene and vaginal estrogen products may be more appropriate pharmacological options for postmenopausal sexual dysfunction and carry FDA approval in that population 30.

How Long Does Aetna Take to Process a Flibanserin PA?

Standard non-urgent PA requests through CVS Caremark (Aetna's PBM) must be adjudicated within 72 hours under ACA regulations. Urgent requests, certified by the prescriber as clinically time-sensitive, require a response within 24 hours 11. In practice, incomplete submissions (missing REMS number, absent distress scale scores, undocumented step therapy) extend processing time because the PA reviewer will pend the request and send a deficiency notice rather than approve.

Prescribers who submit complete initial PA packets, including office notes, step therapy documentation, REMS certification number, and a medical necessity letter, report faster adjudication than those whose submissions require follow-up 31.